Zobrazeno 1 - 10
of 13
pro vyhledávání: '"David Flyer"'
Autor:
Ye Liu, Bin Zhou, Nita Patel, Gale Smith, Larry Ellingsworth, Michael J. Massare, Maggie Lewis, James F. Cummings, David Flyer, Greg Glenn
Publikováno v:
Vaccine. 35:5366-5372
Influenza viruses frequently acquire mutations undergoing antigenic drift necessitating annual evaluation of vaccine strains. Highly conserved epitopes have been identified in the hemagglutinin (HA) head and stem regions, however, current influenza v
Autor:
Bin Zhou, Larry Elllingsworth, Ye Liu, Gregory M. Glenn, Jing-Hui Tian, David Flyer, Gale Smith, Eddie Sullivan, Hua Wu, James F. Cummings
Publikováno v:
Vaccine. 35:4079-4087
Clostridium difficile is the number one cause of nosocomial antibiotic-associated diarrhea in developed countries. Historically, pathogenesis was attributed two homologous glucosylating toxins, toxin-A (TcdA) and toxin-B (TcdB). Over the past decade,
Autor:
Michael J. Massare, Gregory M. Glenn, David Flyer, Bin Zhou, Sapeckshita Agrawal, Gale Smith, Vivek Shinde, Michelle Spindler, Louis Fries, Timothy J. Hahn, Iksung Cho, Yukun Wu, D Nigel Thomas, Elizabeth Lindner, Amy Fix, Joyce S Plested
Publikováno v:
New England Journal of Medicine. 378:2346-2348
Improving the Influenza Vaccine Many approaches are being sought to improve the vaccine against influenza virus. In this report, data on the immunogenicity of a nanoparticle vaccine with a baculovi...
Autor:
Jing-Hui Tian, Michael J. Massare, Vadim A. Ivanov, Robert C. Welliver, Larry Ellingsworth, Gale Smith, Hanxin Lu, James F. Papin, Mimi Guebre-Xabier, David Flyer, Greg Glenn, Alisha Preno
Publikováno v:
Vaccine. 38(5)
Globally, human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infection in infants and young children. There are no licensed vaccines despite the high worldwide disease burden. RSV fusion (F) glycoprotein vaccine is t
Autor:
Xiaorui Chen, Jing-Hui Tian, Gale Smith, Jianpeng Ma, Ye Liu, Zhao Wang, Hanxin Lu, Fengyun Ni, Gregory M. Glenn, David Flyer, Nita Patel, Qinghua Wang, Qingqing Xie, Michael J. Massare, Larry Ellingsworth
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0210749 (2019)
PLoS ONE
PLoS ONE
Globally, human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in newborns, young children, and the elderly for which there is no vaccine. The RSV fusion (F) glycoprotein is a major target for vaccine devel
Autor:
David Flyer, Louis Fries, Eloi Kpamegan, Gregory M. Glenn, Somia P. Hickman, Mimi Guebre-Xabier, Gale Smith, Hanxin Lu
Publikováno v:
Vaccine. 33(47):6488-6492
Background Protection of newborns and young infants against RSV disease via maternal immunization mediated by transplacental transfer of antibodies is under evaluation in third-trimester pregnant women with the RSV recombinant F nanoparticle vaccine
Autor:
Richard W. Compans, Yasmine A. Gomaa, Chinglai Yang, Ling Ye, Mark R. Prausnitz, Jean L. Patterson, Gregory M. Glenn, Hua Wu, Fang Lin, Ricardo Carrion, David Flyer, Gale Smith, Ying Liu
Publikováno v:
The Journal of infectious diseases. 218(suppl_5)
In this study, we investigated immune responses induced by purified Ebola virus (EBOV) soluble glycoprotein (sGP) subunit vaccines via intradermal immunization with microneedle (MN) patches in comparison with intramuscular (IM) injection in mice. Our
Autor:
Mark R. Prausnitz, Ricardo Carrion, David Flyer, Jean L. Patterson, Fang Lin, Gregory M. Glenn, Richard W. Compans, Chinglai Yang, Ling Ye, Ying Liu, Yasmine A. Gomaa, Gale Smith, Hua Wu
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Development of a safe and efficacious filovirus vaccine is of high importance to public health. In this study, we compared immune responses induced by Ebola virus (EBOV) glycoprotein (GP) subunit vaccines via intradermal immunization with microneedle
Autor:
Ye V. Liu, Thiagarajan Venkataraman, Gregory M. Glenn, Matthew B. Frieman, Gale Smith, Christopher M. Coleman, David Flyer
Publikováno v:
Vaccine
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike
Autor:
Michael R. Holbrook, Hiroaki Matsushita, Matthew B. Frieman, Jonathan T. Wang, Eddie Sullivan, Ye Liu, Stanley Perlman, Hua Wu, Rudragouda Channappanavar, Reed F. Johnson, Gene G. Olinger, Kanakatte Raviprakash, Elena Postnikova, Lisa E. Hensley, Christopher M. Coleman, Tadeusz J. Kochel, Jincun Zhao, Britini L. Ork, Jin An Jiao, Gregory M. Glenn, Gale Smith, Wensheng Nie, Jens H. Kuhn, Thomas C. Luke, Gabriel Defang, David Flyer
Publikováno v:
Nature Reviews. Drug Discovery
As of 13 November 2015, 1618 laboratory-confirmed human cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, including 579 deaths, had been reported to the World Health Organization. No specific preventive or therapeutic agent